New Hope for Thrombosis Patients: SRSD107 Shows Promise in Treating Blood Clots
Exciting new data from Sirius Therapeutics suggests a potential breakthrough in the treatment of thromboembolic disorders. The company will present preliminary findings from a Phase 1 clinical trial of its innovative siRNA therapeutic, SRSD107, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego.
A Transformative Approach to Blood Clot Prevention
“The data to be presented at ASH 2024 demonstrate a favorable safety and efficacy profile for SRSD107, suggesting its potential as a transformative medicine with semiannual or even annual dosing for patients requiring a chronic anticoagulant,” said Dr. Patrick Yue, Chief Medical Officer of Sirius Therapeutics. “SRSD107’s viability as an anticoagulant is supported by epidemiologic and other data indicating that inhibiting synthesis of FXI may prevent thrombotic events without increasing bleeding risk. We are set to begin a phase-2 study in the coming months.”
StatusEnum
Understanding the Impact of Thromboembolic Disorders
Thromboembolic disorders, characterized by unwanted blood clot formations, are responsible for a staggering number of deaths worldwide. These clots, which can obstruct blood flow, are the underlying cause of myocardial infarction, ischemic stroke, and venous thromboembolism. A study in The Lancet found that thromboembolic disorders are estimated to contribute to as many as one in four deaths globally.
How SRSD107 Works: Targeting the Coagulation Pathway
SRSD107 represents a novel approach to preventing and treating these life-threatening conditions. It is a double-stranded small interfering RNA (siRNA) specifically designed to target human coagulation factor XI (FXI) mRNA. By inhibiting FXI protein expression, SRSD107 effectively blocks the intrinsic coagulation pathway, ultimately preventing the formation of blood clots and potentially offering a safer alternative to existing anticoagulants.
About Sirius Therapeutics: Innovating for Global Health
Sirius Therapeutics is a dynamic biotech company dedicated to developing next-generation siRNA therapies. Their mission is to translate this innovative technology into transformative medicine for patients suffering from chronic diseases. In addition to SRSD107, the company has SRSD101 in development for the treatment of dyslipidemia
Founded in 2021 by a world-class leadership team and investors, Sirius Therapeutics has established both a discovery center in the United States and a translational medicine center in China. The company has secured nearly US$100 million in funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and their leadership team.
What are the next steps in the clinical development of SRSD107?
## New Hope on the Horizon: Interview with Dr. Yue on SRSD107
**Interviewer:** Welcome to the show, Dr. Yue. You recently announced exciting news regarding Sirius Therapeutics’ Phase 1 trial of SRSD107 for the treatment of thromboembolic disorders. Can you tell us more about this groundbreaking development?
**Dr. Yue:** Certainly. Thrombosis, or blood clot formation, is a significant health issue, responsible for a quarter of deaths globally [1]. At Sirius Therapeutics, we’ve been developing SRSD107, an innovative siRNA therapeutic that targets Factor XI, a key protein involved in clot formation. Our Phase 1 trial has shown promising results, demonstrating both safety and efficacy.
**Interviewer:** What makes SRSD107 potentially transformative for patients?
**Dr. Yue:** Currently, many patients requiring chronic anticoagulation, like those prone to deep vein thrombosis or stroke, need daily injections or pills. Our preliminary findings suggest SRSD107 could be administered semiannually or even annually, significantly improving patient convenience and quality of life.
**Interviewer:** What’s the scientific basis for this potential breakthrough?
**Dr. Yue:** Extensive research indicates that inhibiting Factor XI synthesis can prevent thrombosis without significantly increasing bleeding risk [1]. This targeted approach is highly specific and holds great promise for treating these devastating conditions.
**Interviewer:** What are the next steps for SRSD107?
**Dr. Yue:** We’re thrilled with the Phase 1 results and will be presenting them at the upcoming ASH Annual Meeting in December. We are planning to initiate a Phase 2 study in the coming months to further evaluate SRSD107’s efficacy and safety in a larger patient population.
**Interviewer:** This is truly exciting news for the millions affected by thromboembolic disorders. Thank you for sharing this information with us, Dr. Yue.
**Dr. Yue:** It was my pleasure. We at Sirius Therapeutics are dedicated to bringing innovative therapies to patients in need, and we believe SRSD107 has the potential to significantly improve outcomes for those suffering from thromboembolic diseases.